ZEOX supply chain intelligence for Zeo ScientifiX, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Zeo ScientifiX, Inc. (ZEOX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REGEN-THERAPY | REGEN-THERAPY | 92% | pursuant to which ZEO is expected to be positioned as the core supplier of advanced biologic therapeutics to be incorporated into the next-generation regenerative offerings on Regen's clinical platform |
| ONE-SUPPLIER | ONE-SUPPLIER | 90% | During the fiscal year ended October 31, 2024, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $ 135,000 |
| THIRD-PARTY-CONTRACT-MANUFACTURER | THIRD-PARTY-CONTRACT-MANUFACTURER | 90% | Company entered into an exclusive supply agreement with a third-party contract manufacturer in connection with the manufacturing and processing of certain biological products |
| TWO-SUPPLIERS | TWO-SUPPLIERS | 90% | During the fiscal year ended October 31, 2023, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 113,… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ANOTHER-LARGE-DISTRIBUTOR | ANOTHER-LARGE-DISTRIBUTOR | 90% | Company sold products and services totaling approximately $ 106,000 ( 11.3 % ) to another large distributor |
| ANOTHER-LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIB | ANOTHER-LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIB | 90% | Company sold products and services totaling approximately $ 169,000 ( 11.7 % ) to another large medical practice group and distributor |
| INDIVIDUAL-MEDICAL-PRACTICE | INDIVIDUAL-MEDICAL-PRACTICE | 90% | During the year ended October 31, 2023, the Company sold products and services totaling approximately $ 460,000 ( 10.1 % ) to an individual medical practice |
| LARGE-DISTRIBUTOR | LARGE-DISTRIBUTOR | 90% | Company sold products and services totaling approximately $ 108,000 ( 11.5 % ) to a large distributor |
| LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIBUTOR | LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIBUTOR | 90% | Company sold products and services totaling approximately $ 237,000 ( 16.4 % ) to a large medical practice group and distributor |
| EXOTROPIN | EXOTROPIN | 80% | Company is entitled to receive commissions on the net sales value of Exotropin products sold to pre-approved customers introduced by the Company |
| BESPOKE-TRICYCLES-INC | BESPOKE-TRICYCLES-INC | 62% | nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d… |
| BOTH-GREYT-VENTURES-LLC | BOTH-GREYT-VENTURES-LLC | 62% | nd October 31, 2025, the Company’s interest in Exotropin was approximately 5.6%. Both Greyt Ventures, LLC (“Greyt”), a principal shareholder of the Company and Skycrest Holdings, LLC, (“Skycrest”) a … |
| EXOTROPIN-LLC | EXOTROPIN-LLC | 62% | nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d… |
| FORMERLY-ORGANICELL-REGENERATIVE-MEDICINE-INC | FORMERLY-ORGANICELL-REGENERATIVE-MEDICINE-INC | 62% | 0 Fair value of vested options issued - - 953,000 - 953,000 Fair value of vested warrants issued - - 2,450,000 - 2,450,000 Net loss - - - ( 4,705,000 ) ( 4,705,000 ) Balance October 31, 2024 6,344,81… |
| GREYT-VENTURES-LLC | GREYT-VENTURES-LLC | 62% | successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversel… |
| LEGAL-MATTERS-NEUROVIVE-HOLDING-CO-LLC | LEGAL-MATTERS-NEUROVIVE-HOLDING-CO-LLC | 62% | ompany issued 300,000 shares of common stock and 300,000 warrants to purchase shares of common stock. 15 During the three months ended January 31, 2026 and 2025, the Company amortized $ 215,000 and $… |
| NEUROVIVE-HOLDING-CO-LLC | NEUROVIVE-HOLDING-CO-LLC | 62% | ompany issued 300,000 shares of common stock and 300,000 warrants to purchase shares of common stock. 15 During the three months ended January 31, 2026 and 2025, the Company amortized $ 215,000 and $… |
| ORGANICELL-REGENERATIVE-MEDICINE-INC | ORGANICELL-REGENERATIVE-MEDICINE-INC | 62% | nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d… |
| PARAGON-MEDICAL-GROUP-LLC | PARAGON-MEDICAL-GROUP-LLC | 62% | ompany issued 300,000 shares of common stock and 300,000 warrants to purchase shares of common stock. 15 During the three months ended January 31, 2026 and 2025, the Company amortized $ 215,000 and $… |
| SKYCREST-HOLDINGS-LLC | SKYCREST-HOLDINGS-LLC | 62% | successful or that the Company will be able to timely fund the required costs of those activities. Without sufficient cash reserves, the Company’s ability to pursue growth objectives will be adversel… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ZEOX-DEBT-13748 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-02-10. |
| ZEOX-DEBT | Debt stack $58,186 | 90% | Market cache reports total debt of $58,186. |
| ZEOX-DEBT-13747 | Warrants outstanding: 2.86 | 90% | xbrl warrant detail from xbrl 2025-10-31. |